N protein based vaccine against SARS-COV-2 produces a strong T cell immune response to N protein of novel strains
https://doi.org/10.47183/mes.2022.033
Abstract
The second generation COVID-19 vaccines should produce the long-term protective immune response to the existing and novel strains of SARS-CoV-2. The Convacell® vaccine was designed to produce such immune response by using N protein as an antigen. N-protein is not susceptible to fast accumulation of mutations and is highly homologous to nucleocapsid proteins of other β-coronaviruses. The study was aimed to perform in vitro assessment of the Convacell® vaccine ability to produce immune response to the Wuhan, Delta, and Omicron strains. Mononuclear cells of vaccinated volunteers and survivors were subjected to N protein stimulation. After that specific activation of the cells was assessed by flow cytometry. The results showed that a sibstantial percentage of CD4 and CD8 cells produced IFNγ and IL2 in response to stimulation. No significant reduction of the response to strains Delta and Omicron compared to the Wuhan strain was revealed. The findings support the direction of the N protein based vaccine design towards creation of the universal vaccine.
Keywords
About the Authors
S. O. RabdanoRussian Federation
Sevastyan O. Rabdano
Svobody, 52, 198320, Krasnoye Selo, Saint Petersburg
V. E. Mukhin
Russian Federation
Moscow
V. V. Makarov
Russian Federation
Moscow
G. O. Rudakov
Russian Federation
Saint Petersburg
E. A. Ruzanova
Russian Federation
Saint Petersburg
S. A. Arakelov
Russian Federation
Saint Petersburg
M. R. Khaitov
Russian Federation
Moscow
S. M. Yudin
Russian Federation
Moscow
D. S. Kryuchko
Russian Federation
Moscow
I. A. Berzin
Russian Federation
Moscow
A. E. Evtushenko
Russian Federation
Saint Petersburg
V. P. Truhin
Russian Federation
Saint Petersburg
V. I. Skvortsova
Russian Federation
Moscow
References
1. Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. JCM. 2020; 9 (4): 967.
2. Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Review of Anti-infective Therapy. 2021; 19 (7): 877–88.
3. van Oosterhout C, Hall N, Ly H, Tyler KM. COVID-19 evolution during the pandemic – Implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence. 2021; 12 (1): 507–8.
4. WHO Coronavirus (COVID-19) Dashboard. [cited 2022 Sep 2]. Available from: https://covid19.who.int/
5. Siripanthong B, Asatryan B, Hanff TC, Chatha SR, Khanji MY, Ricci F, et al. The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury. JACC: Basic to Translational Science. 2022; 7 (3): 294–308.
6. Martínez-Salazar B, Holwerda M, Stüdle C, Piragyte I, Mercader N, Engelhardt B, et al. COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. Front Cell Dev Biol. 2022; 10: 824851.
7. Liao T, Meng D, Xiong L, Wu S, Yang L, Wang S, et al. Long- Term Effects of COVID-19 on Health Care Workers 1-Year Post- Discharge in Wuhan. Infect Dis Ther. 2022; 11 (1): 145–63.
8. Yewdell JW. Antigenic drift: Understanding COVID-19. Immunity. 2021; 54 (12): 2681–7.
9. Mittal A, Khattri A, Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. Stapleford K, editor. PLoS Pathog. 2022; 18 (2): e1010260.
10. Heinz FX, Stiasny K. Profiles of current COVID-19 vaccines. Wien Klin Wochenschr. 2021; 133(7–8): 271–83.
11. Garcia-Valtanen P, Hope CM, Masavuli MG, Yeow AEL, Balachandran H, Mekonnen ZA, et al. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Reports Medicine. 2022; 3 (6): 100651.
12. Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. IJMS. 2021; 23 (1): 29.
13. Agerer B, Koblischke M, Gudipati V, Montaño-Gutierrez LF, Smyth M, Popa A, et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 + T cell responses. Sci Immunol. 2021; 6 (57): eabg6461.
14. de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, et al. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. Science. 2021; 24 (11): 103353.
15. Dolton G, Rius C, Hasan MS, Wall A, Szomolay B, Behiry E, et al. Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell. 2022; 185 (16): 2936–51.e19.
16. Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, et al. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Reports. 2021; 36 (11): 109708.
17. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Reports Medicine. 2021; 2 (7): 100355.
18. Jamshidi E, Asgary A, Shafiekhani P, Khajeamiri Y, Mohamed K, Esmaily H, et al. Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. Human Vaccines & Immunotherapeutics. 2022; 18 (5): 2037384.
19. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. Dutch RE, editor. J Virol. 2020; 94 (13): e00647-20, /jvi/94/13/JVI.00647-20. atom.
20. Thura M, Sng JXE, Ang KH, Li J, Gupta A, Hong JM, et al. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Bioscience Reports. 2021; 41 (9): BSR20211491.
21. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS- CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181 (7): 1489–501.e15.
22. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus. J Immunol. 2008; 181 (6): 4168–76.
23. Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, et al. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J. 2012; 9 (1): 322.
24. LaMere MW, Moquin A, Lee FEH, Misra RS, Blair PJ, Haynes L, et al. Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance. J Virol. 2011; 85 (10): 5027–35.
25. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, et al. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016; 8: 277–90.
26. Wraith DC, Vessey AE, Askonas BA. Purified Influenza Virus Nucleoprotein Protects Mice from Lethal Infection. Journal of General Virology. 1987; 68 (2): 433–40.
27. Gil L, Lopez C, Lazo L, Valdes I, Marcos E, Alonso R, et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. International Immunology. 2009; 21 (10): 1175–83.
28. Lazo L, Valdes I, Guillén G, Hermida L, Gil L. Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate. Expert Review of Vaccines. 2019; 18 (2): 161–73.
29. Lazo L, Hermida L, Zulueta A, Sánchez J, López C, Silva R, et al. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine. 2007; 25 (6): 1064–70.
30. Brentville V, Vankemmelbeke M, Metheringham R, Symonds P, Cook K, Urbanowicz R, et al. A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants [Internet]. Immunology. 2021 Jun [cited 2021 Jul 6]. Available from: http://biorxiv.org/lookup/doi/10.1101/2021.06.18.448932
31. Coronavirus3D [Internet]. [cited 2022 Sep 2]. Available from: https://coronavirus3d.org/
32. Re3data.Org. GISAID [Internet]. [cited 2022 Sep 2]. Available from: https://www.re3data.org/repository/r3d100010126
33. Virus Pathogen Database and Analysis Resource (ViPR) - Flaviviridae — VIGOR4 Genome Annotation [Internet]. [cited 2022 Sep 2]. Available from: https://www.viprbrc.org/brc/ vigorAnnotator.spg?method=ShowCleanInputPage&decorator=flavi
34. UGENE [Internet]. [cited 2022 Sep 2]. Available from: https://ugene.net/
35. MUSCLE [Internet]. [cited 2022 Sep 2]. Available from: https:// www.drive5.com/muscle
36. Titov A, Shaykhutdinova R, Shcherbakova OV, Serdyuk YV, Sheetikov SA, Zornikova KV, et al. Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2. JCI Insight. 2022; 7 (9): e157699.
37. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374 (6572): abm0829.
38. Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021; 384 (23): 2259–61.
Review
For citations:
Rabdano S.O., Mukhin V.E., Makarov V.V., Rudakov G.O., Ruzanova E.A., Arakelov S.A., Khaitov M.R., Yudin S.M., Kryuchko D.S., Berzin I.A., Evtushenko A.E., Truhin V.P., Skvortsova V.I. N protein based vaccine against SARS-COV-2 produces a strong T cell immune response to N protein of novel strains. Extreme Medicine. 2022;24(3):5-12. https://doi.org/10.47183/mes.2022.033